We are advising McKesson on the transaction

Davis Polk is advising McKesson Corporation on its acquisition of Precision Medicine Group, LLC for approximately $2.25 billion. The transaction is subject to customary closing conditions, including necessary regulatory clearances.

McKesson is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson’s teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments and others to deliver insights, products and services to help make quality care more accessible and affordable.

Precision Medicine Group supports next-generation approaches to drug development and commercialization. Life sciences innovators in biotechnology and pharmaceutical companies rely on Precision Medicine Group to move their discoveries from molecule to market with a breadth of integrated services and technology-enabled products, including biomarker intelligence, lab services, a global clinical research organization, market access consulting and commercialization support.

The Davis Polk corporate team includes partners Alan F. Denenberg, Michael Diz and Jason Bassetti and associates Matthew Franklin and Hannah R. Carter. Partner Patrick E. Sigmon and associate David J. Beer are providing tax advice. The executive compensation team includes partner Adam Kaminsky and associate Josh (Joshua) Ehrhart. Partner Frank Azzopardi is providing intellectual property advice. Members of the Davis Polk team are based in the Northern California, New York and Washington DC offices.

Copy link to share post